DOCSLIB.ORG

Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating P38 MAPK, ERK, and Cyclooxygenase-2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating P38 MAPK, ERK, and Cyclooxygenase-2 Published OnlineFirst June 13, 2012; DOI: 10.1158/1078-0432.CCR-11-3348 Clinical Cancer Human Cancer Biology Research Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2 Ling-Yen Chung1, Shye-Jye Tang6, Guang-Huan Sun3, Teh-Ying Chou4, Tien-Shun Yeh2, Sung-Liang Yu5, and Kuang-Hui Sun1 Abstract Purpose: This study is aimed at investigating the role and novel molecular mechanisms of galectin-1 in lung cancer progression. Experimental Design: The role of galectin-1 in lung cancer progression was evaluated both in vitro and in vivo by short hairpin RNA (shRNA)-mediated knockdown of galectin-1 in lung adenocarcinoma cell lines. To explore novel molecular mechanisms underlying galectin-1–mediated tumor progression, we analyzed gene expression profiles and signaling pathways using reverse transcription PCR and Western blotting. A tissue microarray containing samples from patients with lung cancer was used to examine the expression of galectin-1 in lung cancer. Results: We found overexpression of galectin-1 in non–small cell lung cancer (NSCLC) cell lines. Suppression of endogenous galectin-1 in lung adenocarcinoma resulted in reduction of the cell migration, invasion, and anchorage-independent growth in vitro and tumor growth in mice. In particular, COX-2 was downregulated in galectin-1–knockdown cells. The decreased tumor invasion and anchorage-independent growth abilities were rescued after reexpression of COX-2 in galectin-1–knockdown cells. Furthermore, we found that TGF-b1 promoted COX-2 expression through galectin-1 interaction with Ras and subsequent activation of p38 mitogen-activated protein kinase (MAPK), extracellular signal–regulated kinase (ERK), and NF-kB pathway. Galectin-1 knockdown sensitized lung cancer cells to platinum-based chemotherapy (cisplatin). In addition, galectin-1 and COX-2 expression was correlated with the progression of lung adenocarcinoma, and high clinical relevance of both proteins was evidenced (n ¼ 47). Conclusions: p38 MAPK, ERK, and COX-2 activation are novel mediators for the galectin-1–promoted tumor progression and chemoresistance in lung cancer. Galectin-1 may be an innovative target for combined modality therapy for lung cancer. Clin Cancer Res; 1–11. Ó2012 AACR. Introduction (NSCLC; ref. 1). The 5-year survival rate of most patients Lung cancer is the leading cause of cancer-associated with advanced NSCLCs is only 9% to 15% (2). Combina- death worldwide. Approximately, 85% of lung cancer is tion cytotoxic chemotherapy results in a modest increase in histologically classified as non–small cell lung cancer survival at the cost of high toxicity (3). EGF receptor- tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib and erlotinib, are commonly used for patients with advanced Authors' Affiliations: 1Department of Biotechnology and Laboratory Sci- adenocarcinoma. However, clinical reports show that only ence in Medicine, National Yang-Ming University, and Department of Edu- cation and Research, Taipei City Hospital; 2Institute of Anatomy and Cell 10% of patients with NSCLCs respond to gefitinib or Biology, National Yang-Ming University; 3Division of Urology, Department of erlotinib (4, 5). Therefore, the development of novel molec- Surgery, Tri-Service General Hospital and National Defense Medical Center; ular approaches is of particular importance for combined 4Department of Pathology and Laboratory Medicine, Taipei Veterans Gen- eral Hospital; 5Department of Clinical Laboratory Sciences and Medical modality treatments of lung cancer. Biotechnology, National Taiwan University, Taipei; and 6Institute of Marine Galectins have high affinity to b-galactoside and share a Biotechnology, National Taiwan Ocean University, Keelung, Taiwan conserved carbohydrate recognition domain (6, 7). Fifteen Note: Supplementary data for this article are available at Clinical Cancer mammalian galectins have been identified and divided into Research Online (http://clincancerres.aacrjournals.org/). 3 subtypes: proto-type, chimera, and tandem-repeat type Corresponding Author: Kuang-Hui Sun, Department of Biotechnology (6). Galectins are involved in a wide range of physiologic and Laboratory Science in Medicine, National Yang-Ming University; Department of Education and Research, Taipei City Hospital, No. 155, process such as cell adhesion, cell-cycle progression, and Sec. 2, Lie-Nong St., Taipei 112, Taiwan. Phone: 886-2-2826-7228; Fax: apoptosis. Galectin-1, classified as a proto-type galectin, is 886-2-2826-4092; E-mail: [email protected] well known to be involved in the initiation, amplification, doi: 10.1158/1078-0432.CCR-11-3348 and resolution of inflammatory responses (8). In addition, Ó2012 American Association for Cancer Research. galectin-1 is secreted in large amounts from tumor cells and www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2012 American Association for Cancer Research. Published OnlineFirst June 13, 2012; DOI: 10.1158/1078-0432.CCR-11-3348 Chung et al. galectin-1 in lung cancer. Galectin-1 could enhance expres- Translational Relevance sion of COX-2, and its metabolite, prostaglandin E2 Targeted therapeutic approaches have been indicated (PGE2), to promote tumor progression in lung cancer. to improve standard chemotherapy. EGF receptor We suggest that TGF-b1 may promote COX-2 expression (EGFR) inhibitors have been commonly used in lung via Ras/galectin-1 to activate mitogen-activated protein cancer treatment. Unfortunately, clinical data show that kinase (MAPK)/NF-kB pathway. Our results indicate that only 10% of patients with non–small cell lung cancer MAPK/COX-2 activation is a novel mechanism that con- (NSCLC) respond to EGFR inhibitors. Our studies pro- tributes to galectin-1–promoted cancer progression and vide insight into the influence of galectin-1, which is chemoresistance in lung adenocarcinoma and that galec- increasingly recognized as an important factor of regu- tin-1 may be a potential target for drug design in lung latory proteins, in lung cancer development. Suppres- cancer therapy. sion of galectin-1 elicits antitumor activity both in vivo in vitro and and inhibits cancer-relevant signaling path- Materials and Methods ways in NSCLCs. Furthermore, galectin-1 is highly expressed in lung cancer tissues from patients with stage Cell lines III NSCLCs, indicating that galectin-1 may be a predictor Mouse Lewis lung carcinoma-1 [LLC-1; H-2b; American for outcome of patients with NSCLCs. In addition, Type Cell Collection (ATCC no. CRL-1642)] and human galectin-1 knockdown sensitized lung cancer cells to lung adenocarcinoma A549 (ATCC no. CCL-185) were platinum-based chemotherapy (cisplatin). These results obtained from BioResources Collection and Research Cen- suggest that galectin-1 may be a biomarker for prognosis ter. Human NSCLC cell lines including adenocarcinoma and an innovative target for combined modality therapy (EKVX, HOP62, NCI-H23, and NCI-H522), large cell car- for lung cancer. cinoma (HOP92 and NCI-H460), squamous cell carcinoma (NCI-H226), and bronchioloalveolar cell carcinoma (NCI- H322M) cell lines were purchased from the National Can- cer Institute (Bethesda, MD). PC-9 lung adenocarcinoma cell line was a kind gift from Dr. A. Maan-Yuh Lin (National promotes immunosuppression by inducing apoptosis of Yang-Ming University, Taipei, Taiwan). HEK293T cell line activated T cells (9). It also contributes to various steps in was a kind gift from Dr. Jason C. Huang (National Yang- tumor progression such as transformation, angiogenesis, Ming University). and metastasis (10). It has been reported that galectin-1 exhibits opposing biologic effects, depending on the phys- icochemical properties of the protein and the target cell type Mouse model b and status (11). Extracellular galectin-1–induced antiproli- Male C57BL/6 (H-2 ; 6–8 weeks of age) mice were ferative effects result from the inhibition of the Ras/mito- purchased from National Laboratory Animal Center (Tai- gen-activated protein (MAP)-ERK (MEK)/extracellular sig- pei, Taiwan). These animals were raised under specific nal–regulated kinase (ERK) pathway and transcriptional pathogen-free conditions in the Animal Center of National induction of p27 (12), whereas intracellular galectin-1 Yang-Ming University in accordance with the regulations of exhibits specificity toward H-Ras and triggers the ERK path- the Animal Care Committee of National Yang-Ming Uni- in vivo way for tumor transformation (13, 14). Moreover, galectin- versity. To determine the tumor growth , C57BL/6  1 accumulation in the peritumoral stroma of ovary and mice were subcutaneously inoculated with tumor cells (2 5 m breast carcinomas regulates both cancer cell proliferation 10 /100 L cells). Tumor volume was measured with a   3 and invasiveness (15–17). Recent studies report that caliper and calculated as length width height (in cm )at galectin-1 activates carcinoma-associated fibroblasts and intervals of 3 days. increases MCP-1 secretion of oral squamous cell carcinoma, which promotes tumor progression and metastasis (15). Tissue microarrays and immunohistochemistry The contradictory effects of galectin-1 on regulating cancer Tissue array slides were purchased from Biomax (US progression still remain to be elucidated. Biomax, Inc.). The company provided certified documents Galectin-1–expressing lung tumors have been shown to that all human tissue samples were collected with informed have poor prognosis (18). Invasiveness of tumor cells has consent
Load more

Recommended publications
  • Galectin-4 Interaction with CD14 Triggers the Differentiation of Monocytes Into Macrophage-Like Cells Via the MAPK Signaling Pathway
    Immune Netw. 2019 Jun;19(3):e17 https://doi.org/10.4110/in.2019.19.e17 pISSN 1598-2629·eISSN 2092-6685 Original Article Galectin-4 Interaction with CD14 Triggers the Differentiation of Monocytes into Macrophage-like Cells via the MAPK Signaling Pathway So-Hee Hong 1,2,3,4,5, Jun-Seop Shin 1,2,3,5, Hyunwoo Chung 1,2,4,5, Chung-Gyu Park 1,2,3,4,5,* 1Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul 03080, Korea 2Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul 03080, Korea 3Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea 4Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea 5Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03080, Korea Received: Jan 28, 2019 ABSTRACT Revised: May 13, 2019 Accepted: May 19, 2019 Galectin-4 (Gal-4) is a β-galactoside-binding protein mostly expressed in the gastrointestinal *Correspondence to tract of animals. Although intensive functional studies have been done for other galectin Chung-Gyu Park isoforms, the immunoregulatory function of Gal-4 still remains ambiguous. Here, we Department of Microbiology and Immunology, Seoul National University College of Medicine, demonstrated that Gal-4 could bind to CD14 on monocytes and induce their differentiation 103 Daehak-ro, Jongno-gu, Seoul 03080, into macrophage-like cells through the MAPK signaling pathway. Gal-4 induced the phenotypic Korea. changes on monocytes by altering the expression of various surface molecules, and induced E-mail: [email protected] functional changes such as increased cytokine production and matrix metalloproteinase expression and reduced phagocytic capacity.
    [Show full text]
  • Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
    Published OnlineFirst May 14, 2010; DOI: 10.1158/1078-0432.CCR-09-3064 Molecular Pathways Clinical Cancer Research Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response Christine A. Pratilas1,2 and David B. Solit3,4 Abstract Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclinical and clinical development. These agents offer the possibility of greater efficacy and less toxicity than current therapies for tumors driven by oncogenic mutations in the MAPK pathway. Early clinical results with the BRAF-selective in- hibitor PLX4032 suggest that this strategy will prove successful in a select group of patients whose tu- mors are driven by V600E BRAF. Relief of physiologic feedback upon pathway inhibition may, however, attenuate drug response and contribute to the development of acquired resistance. An im- proved understanding of the adaptive response of cancer cells to MAPK pathway inhibition may thus aid in the identification of those patients most likely to respond to targeted pathway inhibitors and provide a rational basis for tailored combination strategies. Clin Cancer Res; 16(13); 3329–34. ©2010 AACR. Background these genetic alterations activate common downstream effectors of transformation. One of the central regulators of growth factor-induced Activating BRAF mutations are found clustered within cell proliferation and survival in both normal and cancer the P-loop (exon 11) and activation segment (exon 15) cells is the RAS protein.
    [Show full text]
  • Roles of P38α and P38β Mitogen‑Activated Protein Kinase Isoforms in Human Malignant Melanoma A375 Cells
    INTERNATIONAL JOURNAL OF MOleCular meDICine 44: 2123-2132, 2019 Roles of p38α and p38β mitogen‑activated protein kinase isoforms in human malignant melanoma A375 cells SU-YING WEN1,2, SHI-YANN CHENG3,4, SHANG-CHUAN NG5, RITU ANEJA6, CHIH-JUNG CHEN7, CHIH-YANG HUANG8-12* and WEI-WEN KUO5* 1Department of Dermatology, Taipei City Hospital, Renai Branch, Taipei 106; 2Department of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei 112; 3Department of Medical Education and Research and Department of Obstetrics and Gynecology, China Medical University Beigang Hospital, Yunlin 65152; 4Obstetrics and Gynecology, School of Medicine, China Medical University; 5Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 404, Taiwan, R.O.C.; 6Department of Biology, Georgia State University, Atlanta, GA 30303, USA; 7Division of Breast Surgery, Department of Surgery, China Medical University Hospital; 8Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404; 9Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation; 10Center of General Education, Buddhist Tzu Chi Medical Foundation, Tzu Chi University of Science and Technology, Hualien 970; 11Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404; 12Department of Biotechnology, Asia University, Taichung 413, Taiwan, R.O.C. Received March 29, 2019; Accepted September 12, 2019 DOI: 10.3892/ijmm.2019.4383 Abstract. Skin cancer is one of the most common cancers vimentin, while mesenchymal-epithelial transition markers, worldwide. Melanoma accounts for ~5% of skin cancers but such as E-cadherin, were upregulated. Of note, the results causes the large majority of skin cancer-related deaths.
    [Show full text]
  • Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis a Virus Replication
    International Journal of Molecular Sciences Article Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication Tatsuo Kanda 1,* , Reina Sasaki-Tanaka 1, Ryota Masuzaki 1 , Naoki Matsumoto 1, Hiroaki Okamoto 2 and Mitsuhiko Moriyama 1 1 Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan; [email protected] (R.S.-T.); [email protected] (R.M.); [email protected] (N.M.); [email protected] (M.M.) 2 Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-3972-8111 Abstract: Zinc chloride is known to be effective in combatting hepatitis A virus (HAV) infection, and zinc ions seem to be especially involved in Toll-like receptor (TLR) signaling pathways. In the present study, we examined this involvement in human hepatoma cell lines using a human TLR signaling target RT-PCR array. We also observed that zinc chloride inhibited mitogen-activated protein kinase kinase 3 (MAP2K3) expression, which could downregulate HAV replication in human hepatocytes. It is possible that zinc chloride may inhibit HAV replication in association with its inhibition of MAP2K3. In that regard, this study set out to determine whether MAP2K3 could be considered a modulating factor in the development of the HAV pathogen-associated molecular pattern (PAMP) Citation: Kanda, T.; Sasaki-Tanaka, and its triggering of interferon-β production.
    [Show full text]
  • Inhibition of Galectin-1 Sensitizes HRAS-Driven Tumor Growth to Rapamycin Treatment JAMES V
    ANTICANCER RESEARCH 36 : 5053-5062 (2016) doi:10.21873/anticanres.11074 Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment JAMES V. MICHAEL 1, JEREMY G.T. WURTZEL 1 and LAWRENCE E. GOLDFINGER 1,2 1Department of Anatomy and Cell Biology, The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, U.S.A.; 2Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, U.S.A. Abstract. The goal of this study was to develop The rat sarcoma (RAS) genes most prominently associated combinatorial application of two drugs currently either in with cancer, Harvey RAS ( HRAS ), neuroblastoma RAS active use as anticancer agents (rapamycin) or in clinical (NRAS ) and Kirsten RAS ( KRAS ), are ubiquitously expressed trials (OTX008) as a novel strategy to inhibit Harvey RAS and have overlapping, yet non-redundant functions (1). RAS (HRAS)-driven tumor progression. HRAS anchored to the proteins cycle between an active GTP-bound and an inactive plasma membrane shuttles from the lipid ordered (L o) GDP-bound state. Active RAS stimulates mitogenic and domain to the lipid ordered/lipid disordered border upon survival signal transduction by coupling to effectors activation, and retention of HRAS at these sites requires including rapidly accelerated fibrosarcoma (RAF) kinase for galectin-1. We recently showed that genetically enforced L o propagation of the mitogen-activated protein kinase (MAPK) sequestration of HRAS inhibited mitogen-activated protein pathway [RAS/RAF/MAPK kinase (MEK)/extracellular kinase (MAPK) signaling, but not phoshatidylinositol 3- regulated kinase (ERK)], and phosphatidylinositol 3-kinase kinase (PI3K) activation. Here we show that inhibition of (PI3K) pathways (2).
    [Show full text]
  • Mitogen-Activated Protein Kinase Eight Polymorphisms Are Associated With
    Cao et al. BMC Infectious Diseases (2018) 18:274 https://doi.org/10.1186/s12879-018-3166-x RESEARCH ARTICLE Open Access Mitogen-activated protein kinase eight polymorphisms are associated with immune responsiveness to HBV vaccinations in infants of HBsAg(+)/HBeAg(−)mothers Meng Zhuo Cao2,3†, Yan Hua Wu1†, Si Min Wen1, Yu Chen Pan1, Chong Wang4, Fei Kong4, Chuan Wang1,5, Jun Qi Niu4*, Jie Li2* and Jing Jiang1* Abstract Background: Infants born to hepatitis B surface antigen (HBsAg) positive mothers are at a higher risk for Hepatitis B virus (HBV) infection. Host genetic background plays an importantroleindeterminingthestrengthofimmuneresponse to vaccination. We conducted this study to investigate the association between Tumor necrosis factor (TNF) and Mitogen- activated protein kinase eight (MAPK8) polymorphisms and low response to hepatitis B vaccines. Methods: A total of 753 infants of HBsAg positive and hepatitis Be antigen (HBeAg) negative mothers from the prevention of mother-to-infant transmission of HBV cohort were included. Five tag single nucleotide polymorphism (SNPs) (rs1799964, rs1800629, rs3093671, rs769177 and rs769178) in TNF and two tag SNPs (rs17780725 and rs3827680) in MAPK8 were genotyped using the MassARRAY platform. Results: A higher percentage of breastfeeding (P = 0.013) and a higher level of Ab titers were observed in high responders (P < 0.001). The MAPK8 rs17780725 AA genotype increased the risk of low response to hepatitis B vaccines (OR = 3.176, 95% CI: 1.137–8.869). Additionally, subjects with the AA genotype may have a lower Ab titer than subjects with GA or GG genotypes (P = 0.051). Compared to infants who were breastfed, infants who were not breastfed had an increased risk of low response to hepatitis B vaccine (OR = 2.901, 95% CI:1.306–6.441).
    [Show full text]
  • Full Text (PDF)
    654 Vol. 1, 654–664, July 2003 Molecular Cancer Research Expression of Cyclin-Dependent Kinase 6, but not Cyclin-Dependent Kinase 4, Alters Morphology of Cultured Mouse Astrocytes Karen K. Ericson, David Krull, Peter Slomiany, and Martha J. Grossel Department of Biology, Connecticut College, New London, CT Abstract mechanism involving the accumulation of the p53 and p130 Disruption of the pRb pathway is a common mechanism growth-suppressing proteins (6), and activation of cdk6 in tumor formation. The D-cyclin-associated kinases, precedes cdk4 activation in T cells (7, 8). Also, differences in cyclin-dependent kinase (cdk) 4 and cdk6, are important subcellular localization of cdk4 and cdk6 and in the timing of regulators of the G1-S phase transition and are elevated nuclear localization have been noted in several cell types by in several types of cancers, including gliomas. To several researchers (9–12). Data from tumor studies also investigate potential functional differences in these suggest differences in these kinases. Cdk4, and not cdk6, is kinases, mouse astrocytes were taken from chimeric specifically targeted in melanoma (13, 14) while cdk6 activity mice and propagated in tissue culture. These multipolar has been found to be elevated in squamous cell carcinomas (15, tissue-culture astrocytes were infected with viruses 16) and neuroblastomas (17) without alteration of cdk4 activity. expressing either cdk4 or cdk6. Interestingly, expression Cumulatively, these data suggest that cdk4 and cdk6 have of cdk6 resulted in a distinct and rapid morphology unique functions that may be cell-type specific, temporally change from multipolar to bipolar. This change was not regulated, or developmentally distinct.
    [Show full text]
  • Ligand Induction by Galectin 1 Murine CD8 T
    Modulation of O-Glycans and N-Glycans on Murine CD8 T Cells Fails to Alter Annexin V Ligand Induction by Galectin 1 This information is current as Douglas A. Carlow, Michael J. Williams and Hermann J. of September 25, 2021. Ziltener J Immunol 2003; 171:5100-5106; ; doi: 10.4049/jimmunol.171.10.5100 http://www.jimmunol.org/content/171/10/5100 Downloaded from References This article cites 34 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/171/10/5100.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Modulation of O-Glycans and N-Glycans on Murine CD8 T Cells Fails to Alter Annexin V Ligand Induction by Galectin 11 Douglas A. Carlow,2 Michael J. Williams, and Hermann J.
    [Show full text]
  • NLK Functions to Maintain Proliferation and Stemness of NSCLC and Is A
    Suwei et al. Journal of Hematology & Oncology (2015) 8:120 DOI 10.1186/s13045-015-0203-8 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin Dong Suwei1,2, Zeng Liang3, Liu Zhimin2, Li Ruilei2, Zou Yingying4, Li Zhen1,2, Ge Chunlei2, Lai Zhangchao2, Xue Yuanbo2, Yang Jinyan2, Li Gaofeng5* and Song Xin1,2* Abstract Objective: Nemo-like kinase (NLK) is an evolutionarily conserved serine/threonine kinase that regulates the activity of a wide range of signal transduction pathways. Metformin, an oral antidiabetic drug, is used for cancer prevention. However, the significance and underlying mechanism of NLK and metformin in oncogenesis has not been fully elucidated. Here, we investigate a novel role of NLK and metformin in human non-small cell lung cancer (NSCLC). Materials and methods: NLK expression was analyzed in 121 NSCLCs and 92 normal lung tissue samples from benign pulmonary disease. Lentivirus vectors with NLK-shRNA were used to examine the effect of NLK on cell proliferation and tumorigenesis in vitro. Then, tumor xenograft mouse models revealed that NLK knockdown cells had a reduced ability for tumor formation compared with the control group in vivo. Multiple cell cycle regulator expression patterns induced by NLK silencing were examined by western blots in A549 cells. We also employed metformin to study its anti-cancer effects and mechanisms. Cancer stem cell property was checked by tumor sphere formation and markers including CD133, Nanog, c-Myc, and TLF4. Results: Immunohistochemical (IHC) analysis revealed that NLK expression was up-regulated in NSCLC cases (p <0.001) and correlated with tumor T stage (p < 0.05).
    [Show full text]
  • The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
    International Journal of Molecular Sciences Review The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer 1,2, 1,2, 1,2, 1,2 1,2 Lei Ding y, Jiaqi Cao y, Wen Lin y, Hongjian Chen , Xianhui Xiong , Hongshun Ao 1,2, Min Yu 1,2, Jie Lin 1,2 and Qinghua Cui 1,2,* 1 Lab of Biochemistry & Molecular Biology, School of Life Sciences, Yunnan University, Kunming 650091, China; [email protected] (L.D.); [email protected] (J.C.); [email protected] (W.L.); [email protected] (H.C.); [email protected] (X.X.); [email protected] (H.A.); [email protected] (M.Y.); [email protected] (J.L.) 2 Key Lab of Molecular Cancer Biology, Yunnan Education Department, Kunming 650091, China * Correspondence: [email protected] The authors contributed equally to this work. y Received: 31 December 2019; Accepted: 24 February 2020; Published: 13 March 2020 Abstract: Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose catalytic activities are regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory enzymes involved in cell proliferation through regulating cell-cycle checkpoints and transcriptional events in response to extracellular and intracellular signals. Not surprisingly, the dysregulation of CDKs is a hallmark of cancers, and inhibition of specific members is considered an attractive target in cancer therapy. In breast cancer (BC), dual CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, combined with other agents, were approved by the Food and Drug Administration (FDA) recently for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer (A/MBC), as well as other sub-types of breast cancer.
    [Show full text]
  • 2142.Full.Pdf
    E-Selectin-Dependent Signaling Via the Mitogen-Activated Protein Kinase Pathway in Vascular Endothelial Cells This information is current as Yenya Hu, Jeanne-Marie Kiely, Brian E. Szente, Anthony of September 26, 2021. Rosenzweig and Michael A. Gimbrone, Jr. J Immunol 2000; 165:2142-2148; ; doi: 10.4049/jimmunol.165.4.2142 http://www.jimmunol.org/content/165/4/2142 Downloaded from References This article cites 47 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/165/4/2142.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. E-Selectin-Dependent Signaling Via the Mitogen-Activated Protein Kinase Pathway in Vascular Endothelial Cells1 Yenya Hu,* Jeanne-Marie Kiely,* Brian E. Szente,* Anthony Rosenzweig,† and Michael A. Gimbrone, Jr.2* E-selectin, a cytokine-inducible adhesion molecule, supports rolling and stable arrest of leukocytes on activated vascular endo- thelium.
    [Show full text]
  • Characterization of the Cyclin-Dependent Kinase Inhibitory Domain of the INK4 Family As a Model for a Synthetic Tumour Suppressor Molecule
    Oncogene (1998) 16, 587 ± 596 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule Robin FaÊ hraeus, Sonia LaõÂ n, Kathryn L Ball and David P Lane CRC Cell Transformation Group, Department of Biochemistry, University of Dundee, DD1 4HN Dundee, UK We have previously shown that a 20 amino acid peptide ylation takes place at a time point in the later part of derived from the third ankyrin-like repeat of the the G1 phase that coincides with the restriction point p16CDKN2/INK4a (p16) tumour suppressor protein (residues of the cell cycle in which the cells commit themselves 84 ± 103 of the human p16 protein) can bind to cdk4 and to replicate DNA (Pardee, 1989; Geng and Weinberg, cdk6 and inhibit cdk4-cyclin D1 kinase activity in vitro 1993). The mitogen induced phosphorylation of pRb as well as block cell cycle progression through G1. by CDK-cyclin D kinases releases the E2F transcrip- Substitution of two valine residues corresponding to tion factor from pRb which leads to the induction of amino acids 95 and 96 (V95A and V96A) of the p16 gene products that are essential for the cells to peptide reduces the binding to cdk4 and cdk6 and commence DNA replication (Bandara and La increases its IC0.5 for kinase inhibition approximately Thangue, 1991; Chellappan et al., 1991; Neveins, threefold when linked to the Antennapedia homeodomain 1992; La Thangue, 1994). The release of E2F also carrier sequence.
    [Show full text]